The National Institutes of Health (NIH) is under scrutiny for funding smaller average clinical trial sizes due to their focus on early-stage trials. Biotech companies have a 5x greater chance of drug approval compared to partnering with big pharma at phase 3. NIH announces a $30 million pilot for primary care research aiming to improve clinical trial diversity and pandemic preparedness.
.@NIH will bring clinical research into primary care offices with a $30 million pilot. The NIH's new primary care research network aims to improve representation in clinical science. https://t.co/D6YvGQaVAF
NIH pilots $30 million primary care research initiative. https://t.co/7nncwDkOEA
NIH announces a $30 million pilot to conduct research wheee most people get their care This is a **really big deal** that could really have a huge impact on clinical trial diversity, better study results and pandemic preparedness https://t.co/LDtM1Dh0FM
This is a remarkable statistic from @lumanity. Due to the now 6000+ biotechs & dominance over big pharma of clinical trial starts, biotech now has a 5x greater chance of getting to an approved drug, than partnering with big pharma at phase 3. $XBI https://t.co/qSIlO8Oz2r
Excellent short data-driven post from @MTabarrok. NIH gets criticized for smaller average clinical trial size, but that data point is entirely because they fund more early-stage trials. https://t.co/Pg6gZX0CIT https://t.co/u52T5UhoIm